Marseille-Kliniken AG

euro adhoc: Marseille-Kliniken AG
Quarterly or Semiannual Financial Statements
- Sales increased to EUR 152.1 million after three quarters - More and more positive signs from the Rehabilitation division - Full-year earnings expected to improve compar

---------------------------------------------------------------------   Disclosure announcement transmitted by euro adhoc.   The issuer is responsible for the content of this announcement. ---------------------------------------------------------------------

09.05.2005

In the first three quarters of the fiscal year 2004/05, the Marseille-Kliniken AG (Prime Standard, ISIN DE 0007783003, MKA) was able to further increase sales by 1.2% to EUR 152.1 million (previous year EUR 150.3 million). The earnings pursuant to DVFA/SG (IFRS) amounted to EUR 6.4 million compared with EUR 6.2 million in the previous year. The earnings per share came to EUR 0.53 following EUR 0.51 in the same period one year ago. Thus, due to its strong earnings power the Nursing division was also able to more than offset the decline in earnings in Rehabilitation in the third quarter of the business year 2004/2005. The occupancy rate in the entire Group amounted to 89.3% for the reference period compared with 89.8% one year ago. In addition to the still low utilization rate of the Rehabilitation division, the main reasons are start-up facilities in the Nursing segment.

In its core segment Nursing, in which Marseille-Kliniken provides three quarters of the Group’s total bed capacity, sales and earnings continued to improve. With sales of EUR 111.3 million in this segment during the period under review, Marseille-Kliniken realized a rise in sales of EUR 3 million with respect to the EUR 108.3 million sales generated in the same period one year ago. The earnings pursuant to DVFA/SG (IFRS) once again improved compared with the prior year after the completion of modernization measures. It rose to EUR 9.3 million, up EUR 0.7 million from EUR 8.6 million in the previous year.

There are more and more signs of normalization in the Rehabilitation segment. Even though the division’s sales and earnings were burdened because of restructuring measures, the important key figure for the sector, the utilization rate, improved from 74% to 75.8%. As expected, sales of EUR 39.1 million in the first nine months of the fiscal year 2004/05 were EUR 2.9 million below previous year's level of EUR 42.0 million. The earnings pursuant to DVFA/SG (IFRS) of EUR -2.9 million were still below last year's amount of EUR -2.4 million. However, during the 3rd quarter the loss contribution was reduced by EUR 365,000 (23%) to EUR 1.215 million compared with the same period one year ago. The so far solid development will continue in the remaining three months. Therefore, we expect the growth in the Nursing division and the beginning recovery in the Rehabilitation segment to result in a disproportionately high increase in the DVFA result for the entire business year 2004/2005 (previous year: EUR 7.9 million).

end of announcement                                euro adhoc 09.05.2005 07:22:44
---------------------------------------------------------------------

Further inquiry note: Marseille-Kliniken AG Axel Hölzer CEO Alte Jakobstraße 79/80 10709 Berlin Tel.: +49 30 / 246 32-400 Fax:  +49 30 / 246 32-401

as well as Hillermann Consulting Christian Hillermann Managing Director Eppendorfer Baum 5 20249 Hamburg Tel.: +49 40 / 414069-13 Fax:  +49 40 / 414069-14

Branche: Pharmaceuticals
ISIN:      DE0007783003
WKN:        778300
Index:    Prime Standard, CDAX, Classic All Share, Prime All Share
Börsen:  Berliner Wertpapierbörse / free trade
              Baden-Württembergische Wertpapierbörse / free trade
              Börse Düsseldorf / free trade
              Bremer Wertpapierbörse (BWB) / free trade
              Hamburger Wertpapierbörse / official dealing
              Frankfurter Wertpapierbörse / official dealing



Weitere Meldungen: Marseille-Kliniken AG

Das könnte Sie auch interessieren: